Furthermore, we demonstrate that combined inhibition of two miR‐15/16 targets, FGFR1 and Bcl‐2, has synergistic effects on tumor cell growth encouraging further consideration as novel combination strategy in MPM. The gene discussed is FGFR1; the disease is neoplasm.